Book Value per Share: Prime Medicine Corp (PRME)

Graphic logo of Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. (PRME) faces severe challenges, including zero sales, massive research expenditures, and bioethical uncertainty. However, the development of a unique genome editing method provides protection against dumping and attracts capital, as reflected in the market valuation of the asset, which currently stands at 0.22. An extensive patent portfolio for code "replacement" guarantees future royalties and dominance in the therapy of hereditary pathologies.

Prime Medicine Corp (PRME) Equity per Share: for the period 04/28/2023 - 10/28/2026

primemedicine.com - analytical breakdowns and key metrics (PRME)

- price and consensus price forecast:
Price Chart Prime Medicine Corp|PRME - Consensus Target
- market capitalization data:
Market Capitalization Prime Medicine, Inc.|PRME - Total Enterprise Value
- book capitalization data:
Book Value per Share Prime Medicine|PRME - Accounting Capitalization|Market Value to Book Value Ratio primemedicine.com|PRME - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Prime Medicine, Inc.|PRME - Long-Term Debt to Capital|Short-Term Debt to Equity Prime Medicine|PRME - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Prime Medicine, Inc.|PRME - Company Long-Term Loans and Borrowings|Company Short-Term Debts Prime Medicine
Fundamental company valuation:PRME Prime Medicine Corp
Manufactured products of Prime Medicine

Prime Medicine, Inc. (PRME) maintains stability through its available cash reserves dedicated to funding R&D projects. This resource forms the mathematical basis of net assets, determining the book value per share. This metric measures the business's actual balance sheet foundation, excluding market speculation. The trend in total book value per share reflects the burn rate in the absence of revenue. Analyzing this chart allows for an assessment of the company's cash runway.

Competitors of Prime Medicine, Inc. (PRME)

TEM: Net Assets per Single Share|QGEN - Accounting Value per Share|Book Value per Share IONS|repligen.com (RGEN) - Net Asset Value per Share|Book Value per Share Avidity Biosciences, Inc. (RNA)|Equity per Share CRSP|Net Assets per Single Share Sema4 WGS|Equity per Share Ultragenyx Corp (RARE)|Book Value per Share BEAM (Beam Therapeutics Inc.)|sarepta.com - Book Value per Share|Net Assets per Single Share Twist Bioscience, Inc.|TXG: Share Book Value|Net Assets per Single Share Intellia NTLA|Stoke Corp (STOK) - Accounting Value of a Share|BLFS: Book Value per Share|Net Assets per Share WVE|Net Assets per Single Share MAZE (Maze Therapeutics)|Accounting Value per Share Sionna Therapeutics, Inc. (SION)|TSHA: Book Value per Share|QURE - Net Asset Value per Share|Accounting Value per Share MeiraGTx Holdings plc (MGTX)|RGNX: Accounting Value of a Share|SLDB (Solid Biosciences) - Net Assets per Single Share|Ocugen Inc (OCGN) - Accounting Value per Share|Book Value per Share PACB (Pacific Biosciences of California)|Net Asset Value per Share Benitec Corp|Book Value per Share Design Therapeutics DSGN|Equity per Share rocketpharma.com (RCKT)|Book Value per Share FDMT|Net Assets per Share Lexeo Therapeutics Inc. LXEO|KRRO: Book Value per Share|EDIT - Accounting Value per Share|Silence Therapeutics - Book Value per Share|PRQR (ProQR Therapeutics) - Net Assets per Share|Net Assets per Single Share Codexis Inc (CDXS)|Equity per Share Sangamo Therapeutics Inc.|Nautilus Biotechnology - Book Value per Share|Net Asset Value per Share Metagenomi Therapeutics MGX|Accounting Value per Share Precision BioSciences, Inc.|Accounting Value of a Share Generation Bio Co GBIO|Book Value per Share BOLD (Boundless Bio)|XCUR: Net Assets per Share|Net Assets per Single Share imunon.com|Phio Pharmaceuticals Corp. (PHIO) - Equity per Share|Book Value per Share MBIO|Accounting Value per Share TransCode (RNAZ)|BNGO (Bionano Genomics, Inc.) - Accounting Value per Share|Net Assets per Share APDN (Applied DNA Sciences Inc)|Bluebird Bio (BLUE) - Net Assets per Single Share|ImmunoPrecise Antibodies Ltd - Share Book Value|Net Assets per Single Share Omega Therapeutics (OMGA)|OMIC: Accounting Value of a Share|RGLS (Regulus Therapeutics Inc.) - Net Assets per Single Share|Syros Pharmaceuticals Inc. (SYRS) - Accounting Value per Share|Book Value per Share TBIO (Codex DNA)|Net Asset Value per Share TRACON Pharmaceuticals, Inc|Book Value per Share Unity Biotechnology UBX